110 related articles for article (PubMed ID: 17089447)
1. Deacetylase inhibitors aid recovery in muscular dystrophy.
Anderson I
Lancet Neurol; 2006 Nov; 5(11):906. PubMed ID: 17089447
[No Abstract] [Full Text] [Related]
2. The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice.
Colussi C; Berni R; Rosati J; Straino S; Vitale S; Spallotta F; Baruffi S; Bocchi L; Delucchi F; Rossi S; Savi M; Rotili D; Quaini F; Macchi E; Stilli D; Musso E; Mai A; Gaetano C; Capogrossi MC
Cardiovasc Res; 2010 Jul; 87(1):73-82. PubMed ID: 20164117
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting Histone Deacetylase 2 (HDAC2) Promotes Functional Recovery From Stroke.
Tang Y; Lin YH; Ni HY; Dong J; Yuan HJ; Zhang Y; Liang HY; Yao MC; Zhou QG; Wu HY; Chang L; Luo CX; Zhu DY
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28982677
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors: Are they here to stay?
Ibrahim RB
Am J Health Syst Pharm; 2010 May; 67(10):791. PubMed ID: 20479099
[No Abstract] [Full Text] [Related]
5. Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia.
Einsiedel HG; Kawan L; Eckert C; Witt O; Fichtner I; Henze G; Seeger K
Leukemia; 2006 Aug; 20(8):1435-6. PubMed ID: 16810202
[No Abstract] [Full Text] [Related]
6. SIRT1: A Novel Target for the Treatment of Muscular Dystrophies.
Kuno A; Horio Y
Oxid Med Cell Longev; 2016; 2016():6714686. PubMed ID: 27073590
[TBL] [Abstract][Full Text] [Related]
7. The elusive promise of myostatin inhibition for muscular dystrophy.
Wagner KR
Curr Opin Neurol; 2020 Oct; 33(5):621-628. PubMed ID: 32773450
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
Richon VM; Zhou X; Rifkind RA; Marks PA
Blood Cells Mol Dis; 2001; 27(1):260-4. PubMed ID: 11358386
[No Abstract] [Full Text] [Related]
9. Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
Giannini G; Battistuzzi G; Vignola D
Bioorg Med Chem Lett; 2015 Feb; 25(3):459-61. PubMed ID: 25563890
[TBL] [Abstract][Full Text] [Related]
10. The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?
Grant S
Leukemia; 2004 Dec; 18(12):1931-3. PubMed ID: 15496978
[No Abstract] [Full Text] [Related]
11. Bring back the acetyls - a novel anticancer movement.
Melton L
Lancet Oncol; 2003 Dec; 4(12):710. PubMed ID: 14682340
[No Abstract] [Full Text] [Related]
12. Pioneering studies of histone deacetylase inhibitors in myeloma: signals of activity set the stage for combination therapy trials.
Prince HM
Leuk Lymphoma; 2012 Sep; 53(9):1658-9. PubMed ID: 22260164
[No Abstract] [Full Text] [Related]
13. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
Zhang Y; Fang H; Feng J; Jia Y; Wang X; Xu W
J Med Chem; 2011 Aug; 54(15):5532-9. PubMed ID: 21714538
[TBL] [Abstract][Full Text] [Related]
14. Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer.
Clin Prostate Cancer; 2005 Sep; 4(2):83-5. PubMed ID: 16197607
[No Abstract] [Full Text] [Related]
15. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Duvic M
Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
[TBL] [Abstract][Full Text] [Related]
16. Anticancer drug shows promise against lupus.
Foubister V
Drug Discov Today; 2003 Apr; 8(8):333-4. PubMed ID: 12681930
[No Abstract] [Full Text] [Related]
17. Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice.
Glauben R; Batra A; Stroh T; Erben U; Fedke I; Lehr HA; Leoni F; Mascagni P; Dinarello CA; Zeitz M; Siegmund B
Gut; 2008 May; 57(5):613-22. PubMed ID: 18194985
[TBL] [Abstract][Full Text] [Related]
18. The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.
Prince HM; Bishton M; Harrison S
Leuk Lymphoma; 2008 Mar; 49(3):385-7. PubMed ID: 18297514
[TBL] [Abstract][Full Text] [Related]
19. Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment.
Colussi C; Banfi C; Brioschi M; Tremoli E; Straino S; Spallotta F; Mai A; Rotili D; Capogrossi MC; Gaetano C
Proteomics Clin Appl; 2010 Jan; 4(1):71-83. PubMed ID: 21137017
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
[Next] [New Search]
